A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya - sprookjes - yvandenbroek - TriplyDB

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

http://www.wikidata.org/entity/Q28469062

about

Advances and challenges in malaria vaccine development A review of malaria vaccine clinical projects based on the WHO rainbow table Immunoregulation in human malaria: the challenge of understanding asymptomatic infection The evolution of poxvirus vaccines Characterisation of Plasmodium invasive organelles; an ookinete microneme proteome Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children Identification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profiling Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.Micro-epidemiological structuring of Plasmodium falciparum parasite populations in regions with varying transmission intensities in Africa Novel viral vectored vaccines for the prevention of influenza.Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.Defining childhood severe falciparum malaria for intervention studies Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.Helminth infection and eosinophilia and the risk of Plasmodium falciparum malaria in 1- to 6-year-old children in a malaria endemic area.Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Interactions between age and ITN use determine the risk of febrile malaria in children.Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya.Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya.Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease.Advances and challenges in malaria vaccine development.Estimating individual exposure to malaria using local prevalence of malaria infection in the field.Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations Plasmodium immunomics.The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan children Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection Malaria eradication and elimination: views on how to translate a vision into reality Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.Wind direction and proximity to larval sites determines malaria risk in Kilifi District in Kenya.Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines.A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.Ex vivo monitoring of antigen-specific CD4+ T cells after recall immunization with tetanus toxoid.Experimental Immunization Based on Plasmodium Antigens Isolated by Antibody Affinity.

P2860

Q21032463-CC0BC95F-4AE0-4326-9B9A-33303CEE0CA9 Q21034112-4F454E10-42B5-457C-B142-036CE7BB61BE Q26775212-26B647CE-3396-4935-8C2C-19355478E118 Q26995905-9B6002DD-7B0F-40CF-9AB8-8EE8F1FB2741 Q27972689-A399D86B-810A-4726-AF47-2412217E5FF1 Q28477259-24809EAA-154E-4F63-B9CA-0B7C8BC0B6AD Q28704543-685E3281-BBCA-47F4-B786-F25A288BE8A4 Q28742762-F88BFCB2-5671-470C-8642-DAE8A1150FAA Q29464553-0DF6A9C5-18B3-4091-B471-CE9CA7173924 Q30418570-058F390F-6576-4B16-B63E-CD4AA7EFD591 Q33294698-58E7B694-F983-4384-B305-2BF1FA764340 Q33294896-9F250496-DF36-4486-9EB0-83EBE480E3F5 Q33317265-CB260D4E-5DB6-4F98-8312-F08BE15E19B7 Q33319239-A5C737F6-DD63-4512-8709-C363F22C5B1D Q33320536-B6EF3368-1208-4F1C-9411-F3970E71AEBF Q33520924-10999288-E4F5-4E76-9076-C2198F5E56E2 Q33587443-E87FBD97-F7B3-4F00-851A-0D06DDB79DC5 Q33631268-35058F15-EC53-49CD-BDBC-E31905A0BE51 Q33778747-39CA4883-8570-4D41-B39C-DCF97014303A Q33821137-655B831D-3D74-4D41-B96F-8216CE404C21 Q34145333-D94812D8-88F3-4FE8-A290-8B675058D0FD Q34221250-6E78D699-67BB-4F22-9496-6E98200A2E3B Q34260750-81681053-9E09-497F-9BBB-E86C13C07617 Q34301461-0256D8C5-039A-4D4C-A45B-D664EFBAE230 Q34419934-19133844-8CD8-451E-82E3-0E2F34526003 Q34600408-496CB393-0F7C-4438-91C1-C167D76093C4 Q34612788-A9BA01D8-1670-44B5-AE37-159F2A8E7CC1 Q34634002-6C8FC79F-6ED6-440F-B694-DA05470736BD Q34734075-C585AAAF-5575-4745-ACF0-206B612F2BC3 Q35036289-EAE0BD82-D654-4CA5-A7AF-A951BFCF497C Q35113336-E8480F10-7876-4E30-8DA5-36015ABD0819 Q35571248-96899074-6ADE-445C-97E9-5D58733EA06D Q35581701-FB55571F-0A98-4B54-BA91-C0244B10A552 Q35712522-5BCC675B-4B11-4745-AAF9-B3D4D2A7BA1B Q35741984-075141A5-5636-4D9B-9A41-706DC8DE455C Q35799032-870DB16E-AE1B-4358-9231-817E5A4F3C1D Q35862464-00A4065F-9806-4138-BC93-B4B7FD504387 Q35927866-8150805F-F46E-47D3-AE70-75A7D70AA3DE Q36095146-E69A7ADB-9925-4B0A-984E-E8CDDDD56C88 Q36204459-FDC567B4-EA7C-47B1-8566-B64FD9B3C663

P2860

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

http://www.wikidata.org/entity/Q28469062

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@ast

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@en

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@nl

type

label

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@ast

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@en

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@nl

prefLabel

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@ast

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@en

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@nl

P1433

Q28469062-B5A5BDC1-2BA2-4D52-BE82-E40AB4D892E7

P1476

Q28469062-A227F01A-A439-4A6A-9881-C5B5D00E8AC8

P2093

Q28469062-1AF04BC9-2171-4341-B628-49A403547430

Q28469062-27AD6D63-B867-455C-BB93-1B3375F36D46

Q28469062-5FC6F0FA-8D29-49B3-9750-4F380DE51C8A

Q28469062-87BE6B7C-1875-421B-836D-EB562DFE0C56

Q28469062-8C936FF4-235E-4276-93AD-B4AD4DBCB98E

Q28469062-D7B1A203-636F-467C-867E-9B27BCECC8DC

Q28469062-FE7AFF17-818F-47F6-A580-69A7B75702F3

P2860

Q28469062-00D007F5-107C-4427-A79A-2927D8DBAD5D

Q28469062-03AB3D4A-5EBD-4C48-8264-BCF57C3719C0

Q28469062-0CC49812-87A1-42D3-BF3E-DB9B90F09CAE

Q28469062-0FAB9E90-7EA8-4F71-BD22-78F43C67EA9A

Q28469062-101FD3B1-5587-45AA-B264-6723F5246FA0

Q28469062-18C3FC60-3BF9-422D-9FD4-498ED94E97D5

Q28469062-1ED86E9B-DA56-456A-84A8-8F13B45FED43

Q28469062-2365156C-7C7C-44E0-AC38-C6FF6D3068EB

Q28469062-23A20B73-7D41-4BEC-AFAE-1DF1B1D7F3DB

Q28469062-265972E0-84A1-4ADC-8BFD-8722C3C944F7

P304

Q28469062-BD3408F6-C8D6-4934-819B-9E815CD1AF63

P31

Q28469062-4BBDB533-AC52-4023-9ED6-2462C4DFEC81

P3181

Q28469062-4224725B-D9DB-4E52-9711-E24FCFF66C3A

P356

Q28469062-0DAA64EA-4AEC-4B0D-AF54-581FD3AB2766

P407

Q28469062-D0C9966E-00FA-48E2-BF1B-99F2FD9D2BD5

P433

Q28469062-A8A7BC61-B167-4198-8FE2-EA37780F5D8B

P478

Q28469062-5DAD4A4C-ACEB-4E9C-8FAE-C46E164E4769

P50

Q28469062-19510F28-C041-4B7E-8D86-2AD1C38CF6B4

Q28469062-1B369611-50B5-42DB-916D-5BE81F2C7185

Q28469062-2895B5ED-6B68-4BE2-A9F8-DA85FDA917F4

Q28469062-639812E2-9186-4EE8-A7CB-442C912184F9

Q28469062-876E85B6-24AF-48AD-B81D-4437E84F3DEA

Q28469062-98A2F548-4B13-4FC6-8BDF-27AEE4EA16FE

Q28469062-B5E13FD2-1BE0-4E2F-9171-7394ED33C464

Q28469062-D0A6F302-52A8-4962-B65D-5F324E6E9EED

Q28469062-ECCD73D4-F2E5-4238-9894-47A2E9F326FE

P577

Q28469062-A13AB1A9-97D2-424A-B6B0-84E773A83794

P5875

Q28469062-0A0F6BC9-B14B-47C0-8657-AB4FBFB3AA40

P698

Q28469062-4B750A40-C42E-4AF8-883B-874075616929

P921

Q28469062-0FEAEE56-97F6-436E-8626-DB23A217D18D

Q28469062-35BF1179-119F-4E9E-BB20-993787623D50

P932

Q28469062-52442B9F-81CA-49C4-8A73-F736CF20BA4F

P3181

P356

JOURNAL.PCTR.0010029

P1433

PLOS Clinical Trials

P1476

A phase 2b randomised trial of ...... E-TRAP among children in Kenya

@en

P2093

Brett Lowe

http://www.w3.org/2001/XMLSchema#string

Caroline Gikonyo

http://www.w3.org/2001/XMLSchema#string

Catherine Molyneux

http://www.w3.org/2001/XMLSchema#string

Jedidah Mwacharo

http://www.w3.org/2001/XMLSchema#string

Norbert Peshu

http://www.w3.org/2001/XMLSchema#string

Oscar Kai

http://www.w3.org/2001/XMLSchema#string

Tabitha Mwangi

http://www.w3.org/2001/XMLSchema#string

P2860

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

Common west African HLA antigens are associated with protection from severe malaria

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

Diagnosis of invasive pneumococcal disease among children in Kenya with enzyme-linked immunosorbent assay for immunoglobulin G antibodies to pneumococcal surface adhesin A

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.

The global distribution and population at risk of malaria: past, present, and future

Progress in DNA-based heterologous prime-boost immunization strategies for malaria.

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.

Reduced cord blood immune effector-cell responsiveness mediated by CD4+ cells induced in utero as a consequence of placental Plasmodium falciparum infection.

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.

P304

e29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4884840

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PCTR.0010029

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Adrian V. S. Hill

Sarah Catherine Gilbert

Paul J. Milligan

Stephen M Todryk

P577

2006-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6741695

http://www.w3.org/2001/XMLSchema#string

P698

17053830

http://www.w3.org/2001/XMLSchema#string

P921

P932

1617125

http://www.w3.org/2001/XMLSchema#string